Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...

LyondellBasell's strategic focus on low-cost and circular solutions positions it for long-term growth. Read why I maintain my ...

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), retaining ...

In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on Janux Therapeutics Inc (JANX – Research ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

Richard DiIorio, Chief Executive Officer of InfuSystem, said, "Our third quarter financial results reflect the forecasted acceleration in our business in the second half of the year. We saw ...

PACS Group stock has dropped nearly 33% since Monday following a scathing report from a forensic financial firm that accused ...

Q3 2024 Earnings Call Transcript November 5, 2024 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.98, expectations were $-1.13. Operator: Good day, everyone, and welcome ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to say the least. And as of early November, there's one more big green flag ...

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS ... Nasdaq Delisting and Subsequent ...

Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET. Company Participants. Rick Barry - President & Chief Executive Officer Eric Scho ...

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided an ...